Association Between High-Avidity T-Cell Receptors, Induced by alpha-Fetoprotein - Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma

作者：Nakagawa Hidetoshi; Mizukoshi Eishiro^*; Kobayashi Eiji; Tamai Toshikatsu; Hamana Hiroshi; Ozawa Tatsuhiko; Kishi Hiroyuki; Kitahara Masaaki; Yamashita Tatsuya; Arai Kuniaki; Terashima Takeshi; Iida Noriho; Fushimi Kazumi; Muraguchi Atsushi; Kaneko Shuichi

来源：Gastroenterology, 2017, 152(6): 1395-+.

DOI：10.1053/j.gastro.2017.02.001

• Epitope
• Immunotherapy
• Cytotoxic T Lymphocyte
• Cancer

BACKGROUND & AIMS: Levels of alpha-fetoprotein (AFP) are measured for surveillance and diagnosis of hepatocellular carcinoma (HCC). We performed a phase 1 trial to evaluate the safety and efficacy of AFP-derived peptides as an anti-tumor vaccine for patients with advanced HCC, and characterized induction of AFP-specific T-cell receptors (TCRs). METHODS: We performed a prospective study of 15 patients with HCC seen at Kanazawa University Hospital in Japan from March 2010 through March 2012. Each patient was given a subcutaneous injection of 3 mg AFP-derived peptides (AFP(357) and AFP(403)) in an emulsion with incomplete Freund's adjuvant every other week for at least 6 weeks. Patients were evaluated every 8 weeks by radiologic imaging; adverse events and toxicities were categorized and graded using the common terminology criteria for adverse events. Criteria for discontinuation included unacceptable toxicities and disease progression defined as progressive disease using the Response Evaluation Criteria In Solid Tumors criteria. Patients' immune responses were monitored using an interferon-gamma enzyme-linked immunospot assay. Peptide-specific TCRs were assessed using a rapid TCR cloning and evaluation system. The observation period was 730 days. A complete response was defined as the disappearance of all tumors; stable disease was defined as tumors whose total diameter remained between >70% and <120% of the baseline measurement, without new lesions. RESULTS: We did not observe any serious adverse reactions to the peptides, which were well tolerated. Of the 15 patients who received at least 3 injections, 5 (33%) had an immune response to the peptides. One of the 15 patients had a complete response and disease stabilized in 8 patients. In 4 of the 15 patients, we detected AFP(357)-specific CD8 T cells; we cloned 14 different TCRs with different avidities for the peptide. A TCR with the highest avidity was observed in the patientwho achieved a complete response for more than 2 years. CONCLUSIONS: In a phase 1 trial, administration of AFP-derived peptides to 15 patients with HCC did not cause adverse events and produced T cells with receptors that reacted to the peptides; 1 patient had a complete response and tumor growth slowed in 8 patients. T cells from the patient with a complete response expressed a highly functional TCR induced by the peptide vaccines. UMIN-CTR no: UMIN000003514.

• 出版日期2017-5